Post by BioPharma APAC

Jurgi Camblong, CEO and Co-Founder of SOPHiA GENETICS, said: "Integrating our universal platform with leading sequencing technologies such as the Element AVITI system allows healthcare organizations, regardless of size or geography, to adopt innovative, AI-driven technologies while keeping genomic research local. This partnership aligns with our shared goals of democratizing access to research that supports precision medicine globally, bringing data-driven decisions closer to home, and extending the reach of our respective technologies." Molly He, CEO and Co-Founder of Element Biosciences, said: "Pairing Element's cutting-edge AVITI and AVITI24 systems with SOPHiA GENETICS' powerful AI analytics is a game-changer for the genomics community. This collaboration doesn't just streamline workflows - it redefines what's possible in sequencing, delivering richer insights, faster results and unprecedented accessibility. Together, we're breaking down barriers to enable the future of precision medicine and empower every lab, everywhere, to do more with their data." #SOPHiAGENETICS #ElementBiosciences #PrecisionMedicine #Genomics #AIinHealthcare #NextGenSequencing #NGS #MultiOmics #HealthcareInnovation #BiotechPartnership #DataDrivenMedicine #RareDisease #Oncology #GenomicWorkflows #LabTech https://lnkd.in/dikEGBqD